Skip to main content
Erschienen in: Reviews in Endocrine and Metabolic Disorders 2/2018

03.10.2018

Curative and palliative surgery in patients with neuroendocrine tumors of the gastro-entero-pancreatic (GEP) tract

verfasst von: Peter E. Goretzki, Martina T. Mogl, Aycan Akca, Johann Pratschke

Erschienen in: Reviews in Endocrine and Metabolic Disorders | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

The incidence of neuroendocrine tumors (NET) increases with age. Lately, the diagnosis of NET was mainly caused by early detection of small NET (<1 cm) in the rectum and stomach, which are depicted by chance during routine and prophylactic endoscopy. Also in patients with large and metastatic pancreatic and intestinal tumors thorough pathologic investigation with use of different immunohistologic markers discovers more neuroendocrine tumors with low differentiation grade (G2-G3) and more neuroendocrine carcinomas (NEC), nowadays, than in former times. While gastric and rectal NET are discovered as small (<1 cm in diameter) and mainly highly differentiated tumors, demonstrating lymph node metastases in less than 10% of the patients, the majority of pancreatic and small bowel NET have already metastasized at the time of diagnosis. This is of clinical importance, since tumor stage and differentiation grade not only influence prognosis but also surgical procedure and may define whether a combination of surgery with systemic biologic therapy, chemotherapy or local cytoreductive procedures may be used. The indication for surgery and the preferred surgical procedure will have to consider personal risk factors of each patient (i.e. general health, additional illnesses, etc.) and tumor specific factors (i.e. tumor stage, grade of differentiation, functional activity, mass and variety of loco regional as well as distant metastases etc.). Together they define, whether radical curative or only palliative surgery can be applied. Altogether surgery is the only cure for locally advanced NET and helps to increase quality of life and overall survival in many patients with metastatic neuroendocrine tumors. The question of cure versus palliative therapy sometimes only can be answered with time, however. Many different aspects and various questions concerning the indication and extent of surgery and the best therapeutic procedure are still unanswered. Therefore, a close multidisciplinary cooperation of colleagues involved in biochemical and localization diagnostics and those active in various treatment areas is warranted to search for the optimal strategy in each individual patient. How far genetic screening impacts survival remains to be seen. Since surgeons do have a central role in the treatment of NET patients, they have to understand the need for integration into such an interdisciplinary team.
Literatur
1.
Zurück zum Zitat Boyar Cetinkaya R, Aagnes B, Thiis-Evensen E, et al. Trends in Incidence of Neuroendocrine Neoplasms in Norway: A Report of 16,075 Cases from 1993 through 2010. Neuroendocrinology. 2017;104(1):1–10.CrossRef Boyar Cetinkaya R, Aagnes B, Thiis-Evensen E, et al. Trends in Incidence of Neuroendocrine Neoplasms in Norway: A Report of 16,075 Cases from 1993 through 2010. Neuroendocrinology. 2017;104(1):1–10.CrossRef
2.
Zurück zum Zitat Zhou X, Xie H, Li J, et al. Factors associated with lymph node metastasis in radically esected rectal carcinoids: a systematic review and meta-analysis. J Gastrointest Surg. 2013;17:1689–97.CrossRef Zhou X, Xie H, Li J, et al. Factors associated with lymph node metastasis in radically esected rectal carcinoids: a systematic review and meta-analysis. J Gastrointest Surg. 2013;17:1689–97.CrossRef
3.
Zurück zum Zitat Chi Y, Du F, Zhao H, et al. Characteristics and long-term prognosis of patients with rectal neuroendocrine tumors. World J Gastroenterol. 2014;20(43):16252–7.CrossRef Chi Y, Du F, Zhao H, et al. Characteristics and long-term prognosis of patients with rectal neuroendocrine tumors. World J Gastroenterol. 2014;20(43):16252–7.CrossRef
4.
Zurück zum Zitat Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–42.CrossRef Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–42.CrossRef
5.
Zurück zum Zitat Petersenn S, Koch CA. Neuroendocrine neoplasms - still a challenge despite major advances in clinical care with the development of specialized guidelines. Rev Endocr Metab Disord. 2017;18(4):373–8.CrossRef Petersenn S, Koch CA. Neuroendocrine neoplasms - still a challenge despite major advances in clinical care with the development of specialized guidelines. Rev Endocr Metab Disord. 2017;18(4):373–8.CrossRef
6.
Zurück zum Zitat Fitzgerald TL, Mosquera C, Lea CS, et al. Primary Site Predicts Grade for Gastroenteropancreatic Neuroendocrine Zumors. Am Surg. 2017;83(7):799–803.PubMed Fitzgerald TL, Mosquera C, Lea CS, et al. Primary Site Predicts Grade for Gastroenteropancreatic Neuroendocrine Zumors. Am Surg. 2017;83(7):799–803.PubMed
7.
Zurück zum Zitat Martin JA, Warner RRP, Aronson A, et al. Lymph Node Metastases in the Prognosis of Gastroenteropancreatic Neuroendocrine Tumors. Pancreas. 2017;46(9):1214–8.CrossRef Martin JA, Warner RRP, Aronson A, et al. Lymph Node Metastases in the Prognosis of Gastroenteropancreatic Neuroendocrine Tumors. Pancreas. 2017;46(9):1214–8.CrossRef
8.
Zurück zum Zitat Scherübl H, Streller B, Stabenow R, et al. Clinically detected gastroenteropancreatic neuroendocrine tumors are on the rise: epidemiological changes in Germany. World J Gastroenterol. 2013;19(47):9012–9.CrossRef Scherübl H, Streller B, Stabenow R, et al. Clinically detected gastroenteropancreatic neuroendocrine tumors are on the rise: epidemiological changes in Germany. World J Gastroenterol. 2013;19(47):9012–9.CrossRef
9.
Zurück zum Zitat Begum N, Wellner U, Thorns C, et al. CUP Syndrome in Neuroendocrine Neoplasia: Analysis of Risk Factors and Impact of Surgical Intervention. World J Surg. 2015;39(6):1443–51.CrossRef Begum N, Wellner U, Thorns C, et al. CUP Syndrome in Neuroendocrine Neoplasia: Analysis of Risk Factors and Impact of Surgical Intervention. World J Surg. 2015;39(6):1443–51.CrossRef
10.
Zurück zum Zitat Fitzgerald TL, Dennis SO, Kachare SD, et al. Increasing incidence of duodenal neuroendocrine tumors: Incidental discovery of indolent disease? Surgery. 2015;158(2):466–71.CrossRef Fitzgerald TL, Dennis SO, Kachare SD, et al. Increasing incidence of duodenal neuroendocrine tumors: Incidental discovery of indolent disease? Surgery. 2015;158(2):466–71.CrossRef
11.
Zurück zum Zitat Strosberg JR, Fine RL, Choi J, et al. First line chemotherapy with capecitabine and temozolomide in patients with metastastic pancreatic endocrine carcinoma. Cancer. 2011;117(2):268–75.CrossRef Strosberg JR, Fine RL, Choi J, et al. First line chemotherapy with capecitabine and temozolomide in patients with metastastic pancreatic endocrine carcinoma. Cancer. 2011;117(2):268–75.CrossRef
12.
Zurück zum Zitat Berardi R, Rinaldi A, Torniai M, et al. Gastrointestinal neuroendocrine tumors: Searching the optimal treatment strategy-- A literature review. Crit Rev Oncol Hematol. 2016;98:264–74.CrossRef Berardi R, Rinaldi A, Torniai M, et al. Gastrointestinal neuroendocrine tumors: Searching the optimal treatment strategy-- A literature review. Crit Rev Oncol Hematol. 2016;98:264–74.CrossRef
13.
Zurück zum Zitat Inzani F, Petrone G, Fadda G, et al. Cytohistology in NET: what is necessary today and what is the future? Rev Endocr Metab Disord. 2017;18(4):381–91.CrossRef Inzani F, Petrone G, Fadda G, et al. Cytohistology in NET: what is necessary today and what is the future? Rev Endocr Metab Disord. 2017;18(4):381–91.CrossRef
14.
Zurück zum Zitat Ito T, Lee L, Jensen RT. Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies. Expert Opin Pharmacother. 2016;17(16):2191–205.CrossRef Ito T, Lee L, Jensen RT. Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies. Expert Opin Pharmacother. 2016;17(16):2191–205.CrossRef
15.
Zurück zum Zitat Landry CS, Brock G, Scoggins CR, et al. A proposed staging system for gastric carcinoid tumors based on an analysis of 1,543 patients. Ann Surg Oncol. 2009;16(1):51–60.CrossRef Landry CS, Brock G, Scoggins CR, et al. A proposed staging system for gastric carcinoid tumors based on an analysis of 1,543 patients. Ann Surg Oncol. 2009;16(1):51–60.CrossRef
16.
Zurück zum Zitat Gladdy RA, Strong VE, Coit D, et al. Defining surgical indications for type I gastric carcinoid tumor. Ann Surg Oncol. 2009;16(11):3154–60.CrossRef Gladdy RA, Strong VE, Coit D, et al. Defining surgical indications for type I gastric carcinoid tumor. Ann Surg Oncol. 2009;16(11):3154–60.CrossRef
17.
Zurück zum Zitat Xie JW, Sun YQ, Feng CY, et al. Evaluation of clinicopathological factors related to the prognosis of gastric neuroendocrine carcinoma. Eur J Surg Oncol. 2016;42(10):1464–70.CrossRef Xie JW, Sun YQ, Feng CY, et al. Evaluation of clinicopathological factors related to the prognosis of gastric neuroendocrine carcinoma. Eur J Surg Oncol. 2016;42(10):1464–70.CrossRef
18.
Zurück zum Zitat Basuroy R, Srirajaskanthan R, Prachalias A, et al. Review article: the investigation and management of gastric neuroendocrine tumours. Aliment Pharmacol Ther. 2014;39(10):1071–84.CrossRef Basuroy R, Srirajaskanthan R, Prachalias A, et al. Review article: the investigation and management of gastric neuroendocrine tumours. Aliment Pharmacol Ther. 2014;39(10):1071–84.CrossRef
19.
Zurück zum Zitat Bartsch D, Waldmann J, Fendrich V, et al. Impact of lymphadenectomy on survival after surgery for sporadic gastrinoma. Br J Surg. 2012;99(9):1234–40.CrossRef Bartsch D, Waldmann J, Fendrich V, et al. Impact of lymphadenectomy on survival after surgery for sporadic gastrinoma. Br J Surg. 2012;99(9):1234–40.CrossRef
20.
Zurück zum Zitat Fischer L, Mehrabi A, Büchler MW. Neuroendocrine tumors of the duodenum and pancreas. Surgical strategy. Chirurg. 2011;82(7):583–90.CrossRef Fischer L, Mehrabi A, Büchler MW. Neuroendocrine tumors of the duodenum and pancreas. Surgical strategy. Chirurg. 2011;82(7):583–90.CrossRef
21.
Zurück zum Zitat Kachare SD, Liner KR, Vohra NA, et al. A modified duodenal neuroendocrine tumor staging schema better defines the risk of lymph node metastasis and disease-free survival. Am Surg. 2014;80(8):821–6.PubMed Kachare SD, Liner KR, Vohra NA, et al. A modified duodenal neuroendocrine tumor staging schema better defines the risk of lymph node metastasis and disease-free survival. Am Surg. 2014;80(8):821–6.PubMed
22.
Zurück zum Zitat Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063–72.CrossRef Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063–72.CrossRef
23.
Zurück zum Zitat Partelli S, Bartsch DK, Capdevilla J, et al. ENETS Consensus Guidelines for Standard of Care in Neuroendocrine Tumours: Surgery for Small Intestinal and Pancreatic Neuroendocrine Tumours. Neuroendocrinology. 2017;105(3):255–65.CrossRef Partelli S, Bartsch DK, Capdevilla J, et al. ENETS Consensus Guidelines for Standard of Care in Neuroendocrine Tumours: Surgery for Small Intestinal and Pancreatic Neuroendocrine Tumours. Neuroendocrinology. 2017;105(3):255–65.CrossRef
24.
Zurück zum Zitat Osera S, Oono Y, Ikematsu H, et al. Endoscopic submucosal resection with a ligation device for the treatment of duodenal neuroendocrine tumors. Surg Endosc. 2016;30(9):3928–32.CrossRef Osera S, Oono Y, Ikematsu H, et al. Endoscopic submucosal resection with a ligation device for the treatment of duodenal neuroendocrine tumors. Surg Endosc. 2016;30(9):3928–32.CrossRef
25.
Zurück zum Zitat Hata T, Motoi F, Ishida M, et al. Effect of Hospital Volume on Surgical Outcomes After Panceaticoduodenectomy: A Systematic Review and Meta-analysis. Ann Surg. 2016;263(4):664–72.CrossRef Hata T, Motoi F, Ishida M, et al. Effect of Hospital Volume on Surgical Outcomes After Panceaticoduodenectomy: A Systematic Review and Meta-analysis. Ann Surg. 2016;263(4):664–72.CrossRef
26.
Zurück zum Zitat Falconi M, Eriksson B, Kaltsas G, et al. ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. Neuroendocrinology. 2016;103(2):153–71.CrossRef Falconi M, Eriksson B, Kaltsas G, et al. ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. Neuroendocrinology. 2016;103(2):153–71.CrossRef
27.
Zurück zum Zitat Mulvey CK, van Loon K, Bergsland EK, et al. Complicated Case Presentation: Management of Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1. Pancreas. 2017;46(3):416–26.CrossRef Mulvey CK, van Loon K, Bergsland EK, et al. Complicated Case Presentation: Management of Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1. Pancreas. 2017;46(3):416–26.CrossRef
28.
Zurück zum Zitat Genc CG, Jilesen AP, Partelli S, et al. A New Scoring System to Predict Recurrent Disease in Grade 1 and 2 Nonfunctional Pancreatic Neuroendocrine Tumors. Ann Surg. 2018;267(6):1148–54.CrossRef Genc CG, Jilesen AP, Partelli S, et al. A New Scoring System to Predict Recurrent Disease in Grade 1 and 2 Nonfunctional Pancreatic Neuroendocrine Tumors. Ann Surg. 2018;267(6):1148–54.CrossRef
29.
Zurück zum Zitat Nell S, Verkooijen HM, Pieterman CRC, et al. Management of MEN1 Related Nonfunctioning Pancreatic NETs: A Shifting Paradigm: Results From the DutchMEN1 Study Group. Ann Surg. 2017;267(6):1155–60.CrossRef Nell S, Verkooijen HM, Pieterman CRC, et al. Management of MEN1 Related Nonfunctioning Pancreatic NETs: A Shifting Paradigm: Results From the DutchMEN1 Study Group. Ann Surg. 2017;267(6):1155–60.CrossRef
30.
Zurück zum Zitat Triponez F, Sadowski SM, Pattou F, et al. Long-term Follow-up of MEN1 Patients Who Do Not Have Initial Surgery for Small ≤2 cm Nonfunctioning Pancreatic Neuroendocrine Tumors, an AFCE and GTE Study: Association Francophone de Chirurgie Endocrinienne & Groupe d'Etude des Tumeurs Endocrines. Ann Surg. 2018;268(1):158–64.PubMed Triponez F, Sadowski SM, Pattou F, et al. Long-term Follow-up of MEN1 Patients Who Do Not Have Initial Surgery for Small ≤2 cm Nonfunctioning Pancreatic Neuroendocrine Tumors, an AFCE and GTE Study: Association Francophone de Chirurgie Endocrinienne & Groupe d'Etude des Tumeurs Endocrines. Ann Surg. 2018;268(1):158–64.PubMed
31.
Zurück zum Zitat Krampitz GW, Norton JA, Poultsides GA, et al. Lymph nodes and survival in pancreatic neuroendocrine tumors. Arch Surg. 2012;147(9):820–7.CrossRef Krampitz GW, Norton JA, Poultsides GA, et al. Lymph nodes and survival in pancreatic neuroendocrine tumors. Arch Surg. 2012;147(9):820–7.CrossRef
32.
Zurück zum Zitat Krauss T, Ferrara AM, Links TP, et al. Preventive medicine of von Hippel-Lindau disease-associated pancreatic neuroendocrine tumors. Endocr Relat Cancer. 2018;25(9):783–93.CrossRef Krauss T, Ferrara AM, Links TP, et al. Preventive medicine of von Hippel-Lindau disease-associated pancreatic neuroendocrine tumors. Endocr Relat Cancer. 2018;25(9):783–93.CrossRef
33.
Zurück zum Zitat Glasker S, Neumann HPH, Koch CA, et al. Von Hippel Lindau Disease. In: De Groot LJ, Chrousos G, Dungan K, et al., editors. www.endotext.org , South Dartmouth (MA): MDText.com, Inc.; 2000-. Last Update Sep 12, 2018. Glasker S, Neumann HPH, Koch CA, et al. Von Hippel Lindau Disease. In: De Groot LJ, Chrousos G, Dungan K, et al., editors. www.endotext.org , South Dartmouth (MA): MDText.​com, Inc.; 2000-. Last Update Sep 12, 2018.
34.
Zurück zum Zitat Nell S, Borel Rinkes IHM, Verkooijen HM, et al. Early and Late Complications After Surgery for MEN1-related Nonfunctioning Pancreatic Neuroendocrine Tumors. Ann Surg. 2018;267(2):352–6.CrossRef Nell S, Borel Rinkes IHM, Verkooijen HM, et al. Early and Late Complications After Surgery for MEN1-related Nonfunctioning Pancreatic Neuroendocrine Tumors. Ann Surg. 2018;267(2):352–6.CrossRef
35.
Zurück zum Zitat Du ZY, Chen S, Han BS, et al. Middle segment pancreatectomy: a safe and organ-preserving option for benign and low-grade malignant lesions. World J Gastroenterol. 2013;19(9):1458–65.CrossRef Du ZY, Chen S, Han BS, et al. Middle segment pancreatectomy: a safe and organ-preserving option for benign and low-grade malignant lesions. World J Gastroenterol. 2013;19(9):1458–65.CrossRef
36.
Zurück zum Zitat Sudo T, Murakami Y, Uemura K, et al. Middle pancreatectomy with pancreaticogastrostomy: a technique, operative outcomes, and long-term pancreatic function. J Surg Oncol. 2010;101(1):61–5.CrossRef Sudo T, Murakami Y, Uemura K, et al. Middle pancreatectomy with pancreaticogastrostomy: a technique, operative outcomes, and long-term pancreatic function. J Surg Oncol. 2010;101(1):61–5.CrossRef
37.
Zurück zum Zitat Andrén-Sandberg A, Ansorge C, Yadav TD. Are There Indications for Total Pancreatectomy in 2016? Dig Surg. 2016;33(4):329–34.CrossRef Andrén-Sandberg A, Ansorge C, Yadav TD. Are There Indications for Total Pancreatectomy in 2016? Dig Surg. 2016;33(4):329–34.CrossRef
38.
Zurück zum Zitat Rosentraeger MJ, Garbrecht N, Anlauf M, et al. Syndromic versus non-syndromic neuroendocrine tumors of the duodenum: comparison of pathological features and biological behavior. Virchows Arch. 2016;468(3):277–87.CrossRef Rosentraeger MJ, Garbrecht N, Anlauf M, et al. Syndromic versus non-syndromic neuroendocrine tumors of the duodenum: comparison of pathological features and biological behavior. Virchows Arch. 2016;468(3):277–87.CrossRef
39.
Zurück zum Zitat Keutgen XM, Nilobul N, Kebebew E. Malignant-functioning neuroendocrine tumors of the pancreas: a survival analysis. Surgery. 2016;159(5):1382–9.CrossRef Keutgen XM, Nilobul N, Kebebew E. Malignant-functioning neuroendocrine tumors of the pancreas: a survival analysis. Surgery. 2016;159(5):1382–9.CrossRef
40.
Zurück zum Zitat Falconi M, Zerbi A, Crippa S, et al. Parenchyma-preserving resections for small onfunctioning pancreatic endocrine tumors. Ann Surg Oncol. 2010;17(6):1621–7.CrossRef Falconi M, Zerbi A, Crippa S, et al. Parenchyma-preserving resections for small onfunctioning pancreatic endocrine tumors. Ann Surg Oncol. 2010;17(6):1621–7.CrossRef
41.
Zurück zum Zitat Akca A, Starke A, Goretzki PE, et al. Early postoperative glucose metabolism after insulinoma resection; abstract: CAEK 2018; LAS 2018. Akca A, Starke A, Goretzki PE, et al. Early postoperative glucose metabolism after insulinoma resection; abstract: CAEK 2018; LAS 2018.
42.
Zurück zum Zitat Rodriguez-Sanjuan JC, Gomez-Ruiz M, Trugeda-Carrera S, et al. Laparoscopic and robotic-assisted digestive surgery: present and future directions. World J Gastroenterol. 2016;22(6):1975–2004.CrossRef Rodriguez-Sanjuan JC, Gomez-Ruiz M, Trugeda-Carrera S, et al. Laparoscopic and robotic-assisted digestive surgery: present and future directions. World J Gastroenterol. 2016;22(6):1975–2004.CrossRef
43.
Zurück zum Zitat Fendrich V, Waldmann J, Bartsch D, et al. Surgical management of pancreatic endocrine tumors. Nat Rev Clin Oncol. 2009;6(7):419–28.CrossRef Fendrich V, Waldmann J, Bartsch D, et al. Surgical management of pancreatic endocrine tumors. Nat Rev Clin Oncol. 2009;6(7):419–28.CrossRef
44.
Zurück zum Zitat Mehrabi A, Fischer L, Hafezi M, et al. A systematic review of localization, surgical treatment options, and outcome of insulinoma. Pancreas. 2014;43(5):675–86.CrossRef Mehrabi A, Fischer L, Hafezi M, et al. A systematic review of localization, surgical treatment options, and outcome of insulinoma. Pancreas. 2014;43(5):675–86.CrossRef
45.
Zurück zum Zitat Thomaschewski M, Neeff H, Keck T, et al. Is there any role for minimally invasive surgery in NET? Rev Endocr Metab Disord. 2017;18(4):443–57.CrossRef Thomaschewski M, Neeff H, Keck T, et al. Is there any role for minimally invasive surgery in NET? Rev Endocr Metab Disord. 2017;18(4):443–57.CrossRef
46.
Zurück zum Zitat Norton JA, Fraker DL, Alexander HR, et al. Surgery increases survival in patients with gastrinoma. Ann Surg. 2006;244(3):410–9.PubMedPubMedCentral Norton JA, Fraker DL, Alexander HR, et al. Surgery increases survival in patients with gastrinoma. Ann Surg. 2006;244(3):410–9.PubMedPubMedCentral
47.
Zurück zum Zitat Pavel M. O’Toole D, Costa F, et al. ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site.14. Neuroendocrinology. 2016;103(2):172–85.CrossRef Pavel M. O’Toole D, Costa F, et al. ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site.14. Neuroendocrinology. 2016;103(2):172–85.CrossRef
48.
Zurück zum Zitat Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97(4):934–59.CrossRef Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97(4):934–59.CrossRef
49.
Zurück zum Zitat Grandhi MS, Lafaro KJ, Pawlik TM. Role of Locoregional and Systemic Approaches for the Treatment of Patients with Metastatic Neuroendocrine Tumors. J Gastrointest Surg. 2015;19(12):2273–82.CrossRef Grandhi MS, Lafaro KJ, Pawlik TM. Role of Locoregional and Systemic Approaches for the Treatment of Patients with Metastatic Neuroendocrine Tumors. J Gastrointest Surg. 2015;19(12):2273–82.CrossRef
50.
Zurück zum Zitat Russolillo N, Vigano L, Razzore P, et al. Survival prognostic factors of gastro-enteric-pancreatic neuroendocrine tumors after primary tumor resection in a single tertiary center: comparison of gastro-enteric and pancreatic locations. Eur J Surg Oncol. 2015;41(6):751–7.CrossRef Russolillo N, Vigano L, Razzore P, et al. Survival prognostic factors of gastro-enteric-pancreatic neuroendocrine tumors after primary tumor resection in a single tertiary center: comparison of gastro-enteric and pancreatic locations. Eur J Surg Oncol. 2015;41(6):751–7.CrossRef
51.
Zurück zum Zitat Sposito C, Droz dit Busset M, Citterio D, et al. The place of liver transplantation in the treatment of hepatic metastases from neuroendocrine tumors: pros and cons. Rev Endocr Metab Disord. 2017;18(4):473–83.CrossRef Sposito C, Droz dit Busset M, Citterio D, et al. The place of liver transplantation in the treatment of hepatic metastases from neuroendocrine tumors: pros and cons. Rev Endocr Metab Disord. 2017;18(4):473–83.CrossRef
52.
Zurück zum Zitat Jann H, Roll S, Couvelard A, et al. Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome. Cancer. 2011;117(15):3332–41.CrossRef Jann H, Roll S, Couvelard A, et al. Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome. Cancer. 2011;117(15):3332–41.CrossRef
53.
Zurück zum Zitat Habbe N, Fendrich V, Heverhagen A, et al. Outcome of surgery for ileojejunal neuroendocrine tumors. Surg Today. 2013;43(10):1168–74.CrossRef Habbe N, Fendrich V, Heverhagen A, et al. Outcome of surgery for ileojejunal neuroendocrine tumors. Surg Today. 2013;43(10):1168–74.CrossRef
54.
Zurück zum Zitat Landry CS, Lin HY, Phan A, et al. Resection of at-risk mesenteric lymph nodes is associated with improved survival in patients with small bowel neuroendocrine tumors. World J Surg. 2013;37(7):1695–700.CrossRef Landry CS, Lin HY, Phan A, et al. Resection of at-risk mesenteric lymph nodes is associated with improved survival in patients with small bowel neuroendocrine tumors. World J Surg. 2013;37(7):1695–700.CrossRef
55.
Zurück zum Zitat Kim MK, Warner RR, Ward SC, et al. Prognostic significance of lymph node metastases in small intestinal neuroendocrine tumors. Neuroendocrinology. 2015;101(1):58–65.CrossRef Kim MK, Warner RR, Ward SC, et al. Prognostic significance of lymph node metastases in small intestinal neuroendocrine tumors. Neuroendocrinology. 2015;101(1):58–65.CrossRef
56.
Zurück zum Zitat Schindl M, Kaczirek K, Passler C, et al. Treatment of small intestinal neuroendocrine umors: is an extended multimodal approach justified? World J Surg. 2002;26(8):976–84.CrossRef Schindl M, Kaczirek K, Passler C, et al. Treatment of small intestinal neuroendocrine umors: is an extended multimodal approach justified? World J Surg. 2002;26(8):976–84.CrossRef
57.
Zurück zum Zitat Paquer A, Walter T, Hervieu V. Surgical management of small bowel neuroendocrine tumors: specific requirements and their impact on staging and prognosis. Ann Surg Oncol. 2015;3:S742–9.CrossRef Paquer A, Walter T, Hervieu V. Surgical management of small bowel neuroendocrine tumors: specific requirements and their impact on staging and prognosis. Ann Surg Oncol. 2015;3:S742–9.CrossRef
58.
Zurück zum Zitat Singer J, Werner F, Koch CA, et al. Ectopic Cushing's syndrome caused by a well differentiated ACTH-secreting neuroendocrine carcinoma of the ileum. Exp Clin Endocrinol Diabetes. 2010;118(8):524–9.CrossRef Singer J, Werner F, Koch CA, et al. Ectopic Cushing's syndrome caused by a well differentiated ACTH-secreting neuroendocrine carcinoma of the ileum. Exp Clin Endocrinol Diabetes. 2010;118(8):524–9.CrossRef
59.
Zurück zum Zitat O'Shea T, Druce M. When should genetic testing be performed in patients with neuroendocrine tumors? Rev Endocr Metab Disord. 2017;18(4):499–515.CrossRef O'Shea T, Druce M. When should genetic testing be performed in patients with neuroendocrine tumors? Rev Endocr Metab Disord. 2017;18(4):499–515.CrossRef
60.
Zurück zum Zitat Kaltsas G, Caplin M, Davies P, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors. Neuroendocrinology. 2017;105(3):245–54.CrossRef Kaltsas G, Caplin M, Davies P, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors. Neuroendocrinology. 2017;105(3):245–54.CrossRef
61.
Zurück zum Zitat Ramage JK, Ahmed A, Ardill J, et al. UK and Ireland Neuroendocrine Tumour Society. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut. 2012;61(1):6–32.CrossRef Ramage JK, Ahmed A, Ardill J, et al. UK and Ireland Neuroendocrine Tumour Society. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut. 2012;61(1):6–32.CrossRef
62.
Zurück zum Zitat Griniatsos J, Michail O. Appendiceal neuroendocrine tumors: Recent insights and clinical implications. World J Gastrointest Oncol. 2010;2(4):192–6.CrossRef Griniatsos J, Michail O. Appendiceal neuroendocrine tumors: Recent insights and clinical implications. World J Gastrointest Oncol. 2010;2(4):192–6.CrossRef
63.
Zurück zum Zitat Boxberger N, Redlich A, Böger C, et al. Neuroendocrine tumors of the appendix in children and adolescents. Pediatr Blood Cancer. 2013;60(1):65–70.CrossRef Boxberger N, Redlich A, Böger C, et al. Neuroendocrine tumors of the appendix in children and adolescents. Pediatr Blood Cancer. 2013;60(1):65–70.CrossRef
64.
Zurück zum Zitat Gustafsson BI, Siddique L, Chan A, et al. Uncommon cancers of the small intestine, appendix and colon: an analysis of SEER 1973-2004, and current diagnosis and therapy. Int J Oncol. 2008;33(6):1121–31.PubMed Gustafsson BI, Siddique L, Chan A, et al. Uncommon cancers of the small intestine, appendix and colon: an analysis of SEER 1973-2004, and current diagnosis and therapy. Int J Oncol. 2008;33(6):1121–31.PubMed
65.
Zurück zum Zitat Kleiman DA, Finnerly B, Beninato T, et al. Features Associated With Metastases Among Well-Differentiated Neuroendocrine (Carcinoid) Tumors of the Appendix: The Significance of Small Vessel Invasion in Addition to Size. Dis Colon Rectum. 2015;58(12):1137–43.CrossRef Kleiman DA, Finnerly B, Beninato T, et al. Features Associated With Metastases Among Well-Differentiated Neuroendocrine (Carcinoid) Tumors of the Appendix: The Significance of Small Vessel Invasion in Addition to Size. Dis Colon Rectum. 2015;58(12):1137–43.CrossRef
66.
Zurück zum Zitat Rossi RE, Luong TV, Caplin ME, et al. Goblet cell appendiceal tumors—management dilemmas and long-term outcomes. Surg Oncol. 2015;24(1):47–53.CrossRef Rossi RE, Luong TV, Caplin ME, et al. Goblet cell appendiceal tumors—management dilemmas and long-term outcomes. Surg Oncol. 2015;24(1):47–53.CrossRef
67.
Zurück zum Zitat Pahlavan PS, Kanthan R. Goblet cell carcinoid of the appendix. World J Surg Oncol. 2005;3:36.CrossRef Pahlavan PS, Kanthan R. Goblet cell carcinoid of the appendix. World J Surg Oncol. 2005;3:36.CrossRef
68.
Zurück zum Zitat Lamarca A, Nonaka D, Lopez-Escola C, et al. Appendiceal Goblet Cell Carcinoids: Management Considerations from a Reference Peritoneal Tumour Service Centre and ENETS Centre of Excellence. Neuroendocrinology. 2016;103(5):500–17.CrossRef Lamarca A, Nonaka D, Lopez-Escola C, et al. Appendiceal Goblet Cell Carcinoids: Management Considerations from a Reference Peritoneal Tumour Service Centre and ENETS Centre of Excellence. Neuroendocrinology. 2016;103(5):500–17.CrossRef
69.
Zurück zum Zitat Smith JD, Reidy DL, Goodman KA, et al. A retrospective review of 126 high-grade neuroendocrine carcinomas of the colon and rectum. Ann Surg Oncol. 2014;21(9):2956–62.CrossRef Smith JD, Reidy DL, Goodman KA, et al. A retrospective review of 126 high-grade neuroendocrine carcinomas of the colon and rectum. Ann Surg Oncol. 2014;21(9):2956–62.CrossRef
70.
Zurück zum Zitat Shafqat H, Ali S, Salhab M, et al. Survival of patients with neuroendocrine carcinoma of the colon and rectum: a population-based analysis. Dis Colon Rectum. 2015;58(3):294–303.CrossRef Shafqat H, Ali S, Salhab M, et al. Survival of patients with neuroendocrine carcinoma of the colon and rectum: a population-based analysis. Dis Colon Rectum. 2015;58(3):294–303.CrossRef
71.
Zurück zum Zitat Sekiguchi M, Sekine S, Sakamoto T, et al. Excellent prognosis following endoscopic resection of patients with rectal neuroendocrine tumors despite the frequent presence of lymphovascular invasion. J Gastroenterol. 2015;50(12):1184–9.CrossRef Sekiguchi M, Sekine S, Sakamoto T, et al. Excellent prognosis following endoscopic resection of patients with rectal neuroendocrine tumors despite the frequent presence of lymphovascular invasion. J Gastroenterol. 2015;50(12):1184–9.CrossRef
72.
Zurück zum Zitat Shields CJ, Tiret E, Winter DC. Carcinoid tumors of the rectum: a multi-institutional international collaboration. Ann Surg. 2010;252(5):750–5.CrossRef Shields CJ, Tiret E, Winter DC. Carcinoid tumors of the rectum: a multi-institutional international collaboration. Ann Surg. 2010;252(5):750–5.CrossRef
73.
Zurück zum Zitat Brieau B, Lepere C, Walter T, et al. Radiochemotherapy Versus Surgery in Nonmetastatic Anorectal Neuroendocrine Carcinoma: A Multicenter Study by the Association des Gastro-Enterologues Oncologues. Medicine (Baltimore). 2015;94(42):e1864.CrossRef Brieau B, Lepere C, Walter T, et al. Radiochemotherapy Versus Surgery in Nonmetastatic Anorectal Neuroendocrine Carcinoma: A Multicenter Study by the Association des Gastro-Enterologues Oncologues. Medicine (Baltimore). 2015;94(42):e1864.CrossRef
74.
Zurück zum Zitat Bacchetti S, Bertozzi S, Londero AP, et al. Surgical treatment and survival in patients with liver metastases from neuroendocrine tumors: a meta-analysis of observational studies. Int J Hepatol. 2013;2013:235040.CrossRef Bacchetti S, Bertozzi S, Londero AP, et al. Surgical treatment and survival in patients with liver metastases from neuroendocrine tumors: a meta-analysis of observational studies. Int J Hepatol. 2013;2013:235040.CrossRef
75.
Zurück zum Zitat Frilling A, Modlin IM, Kidd M, et al. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol. 2014;15(1):e8–21.CrossRef Frilling A, Modlin IM, Kidd M, et al. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol. 2014;15(1):e8–21.CrossRef
76.
Zurück zum Zitat Lesurtel M, Nagorney DM, Mazzaferro V, et al. When should a liver resection be performed in patients with liver metastases from neuroendocrine tumours? A systematic review with practice recommendations. HPB (Oxford). 2015;17(1):17–22.CrossRef Lesurtel M, Nagorney DM, Mazzaferro V, et al. When should a liver resection be performed in patients with liver metastases from neuroendocrine tumours? A systematic review with practice recommendations. HPB (Oxford). 2015;17(1):17–22.CrossRef
77.
Zurück zum Zitat Yuan CH, Wang J, Xiu DR, et al. Meta-analysis of Liver Resection Versus Nonsurgical Treatments for Pancreatic Neuroendocrine Tumors with Liver Metastases. Ann Surg Oncol. 2016;23(1):244–9.CrossRef Yuan CH, Wang J, Xiu DR, et al. Meta-analysis of Liver Resection Versus Nonsurgical Treatments for Pancreatic Neuroendocrine Tumors with Liver Metastases. Ann Surg Oncol. 2016;23(1):244–9.CrossRef
78.
Zurück zum Zitat Du S, Wang Z, Sang X, et al. Surgical resection improves the outcome of the patients with neuroendocrine tumor liver metastases. Medicine (Baltimore). 2015;94(2):e388.CrossRef Du S, Wang Z, Sang X, et al. Surgical resection improves the outcome of the patients with neuroendocrine tumor liver metastases. Medicine (Baltimore). 2015;94(2):e388.CrossRef
79.
Zurück zum Zitat Gaujoux S, Gonen M, Tang L, et al. Synchronous resection of primary and liver metastases for neuroendocrine tumors. Ann Surg Oncol. 2012;19(13):4270–7.CrossRef Gaujoux S, Gonen M, Tang L, et al. Synchronous resection of primary and liver metastases for neuroendocrine tumors. Ann Surg Oncol. 2012;19(13):4270–7.CrossRef
80.
Zurück zum Zitat Bacchetti S, Pasqual EM, Bertozzi S, et al. Curative versus palliative surgical resection of liver metastases in patients with neuroendocrine tumors: a meta-analysis of observational studies. Gland Surg. 2014;3(4):243–51.PubMedPubMedCentral Bacchetti S, Pasqual EM, Bertozzi S, et al. Curative versus palliative surgical resection of liver metastases in patients with neuroendocrine tumors: a meta-analysis of observational studies. Gland Surg. 2014;3(4):243–51.PubMedPubMedCentral
81.
Zurück zum Zitat Watzka FM, Fottner C, Miederer M, et al. Surgical therapy of neuroendocrine neoplasm with hepatic metastasis: patient selection and prognosis. Langenbeck's Arch Surg. 2015;400(3):349–58.CrossRef Watzka FM, Fottner C, Miederer M, et al. Surgical therapy of neuroendocrine neoplasm with hepatic metastasis: patient selection and prognosis. Langenbeck's Arch Surg. 2015;400(3):349–58.CrossRef
82.
Zurück zum Zitat Givi B, Pommier SJ, Thompson AK, et al. Operative resection of primary carcinoid neoplasms in patients with liver metastases yields significantly better survival. Surgery. 2006;140(6):891–7 discussion 897-8.CrossRef Givi B, Pommier SJ, Thompson AK, et al. Operative resection of primary carcinoid neoplasms in patients with liver metastases yields significantly better survival. Surgery. 2006;140(6):891–7 discussion 897-8.CrossRef
83.
Zurück zum Zitat Mandani A, Thomassen I, van Gestel YRBM, et al. Peritoneal metastases from gastroenteropancreatic neuroendocrine tumors: incidence, risk factors and prognosis. Ann Surg Oncol. 2017;24(8):2199–205.CrossRef Mandani A, Thomassen I, van Gestel YRBM, et al. Peritoneal metastases from gastroenteropancreatic neuroendocrine tumors: incidence, risk factors and prognosis. Ann Surg Oncol. 2017;24(8):2199–205.CrossRef
84.
Zurück zum Zitat Keutgen XM, Nilubol N, Glanville J, et al. Resection of primary tumor site is associated with prolonged survival in metastatic nonfunctioning pancreatic neuroendocrine tumors. Surgery. 2016;159(1):311–8.CrossRef Keutgen XM, Nilubol N, Glanville J, et al. Resection of primary tumor site is associated with prolonged survival in metastatic nonfunctioning pancreatic neuroendocrine tumors. Surgery. 2016;159(1):311–8.CrossRef
Metadaten
Titel
Curative and palliative surgery in patients with neuroendocrine tumors of the gastro-entero-pancreatic (GEP) tract
verfasst von
Peter E. Goretzki
Martina T. Mogl
Aycan Akca
Johann Pratschke
Publikationsdatum
03.10.2018
Verlag
Springer US
Erschienen in
Reviews in Endocrine and Metabolic Disorders / Ausgabe 2/2018
Print ISSN: 1389-9155
Elektronische ISSN: 1573-2606
DOI
https://doi.org/10.1007/s11154-018-9469-9

Weitere Artikel der Ausgabe 2/2018

Reviews in Endocrine and Metabolic Disorders 2/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.